Global Lag 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028
January 7, 2022 ⚊ 1 Min read ⚊ Views 134 ⚊ BUSINESSCancer immunotherapy is a novel approach which can reverse tumor immune escape by suppressing immune checkpoint pathways. Several immune checkpoint inhibitors targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have demonstrated durable efficacy against melanoma, renal, lung and other cancers.
Tags: lag 3 inhibitor clinical trials and market, life sciences market research report